Study title: HDM9007 - Clinical observation to evaluate the patient oriented dosages of Palladon® retard with respect to circadian variations in pain intensity (0.1% of patients 10-19 years) (Germany); Protocol No.011-004: Open label, preliminary evaluation of the clinical effectiveness and steady state pharmacokinetics of a controlled release sprinkle formulation of hydromorphone in pediatric patients with chronic cancer pain. (terminated - lack of recruitment)
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Anesthesia and Analgesia [E03] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: HYDROMORPHONE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: Protocol No.011-004 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |